VERU INC. Contract Liability (Deferred Revenue)
VERU INC. (VERU) had Contract Liability (Deferred Revenue) of $400.00 thousand as of 2024-09-30, per its 10-K filed 2024-12-16.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:ContractWithCustomerLiabilityCurrent · last filed 2024-12-16
- 2024-09-30: Contract with Customer, Liability, Current $400.00K.
- 2024-06-30: Contract with Customer, Liability, Current $333.00K.
- 2023-09-30: Contract with Customer, Liability, Current $100.00K; Contract with Customer, Liability, Current as first filed $105.00K.
- 2022-10-01: Contract with Customer, Liability, Current $300.00K.
| Period end | Contract with Customer, Liability, Current | Contract with Customer, Liability, Current as first filed |
|---|---|---|
| 2024-09-30 | $400.00K 10-K · filed 2024-12-16 | |
| 2024-06-30 | $333.00K 10-Q · filed 2024-08-08 | |
| 2023-09-30 | $100.00K 10-K · filed 2024-12-16 | $105.00K 10-Q · filed 2024-08-08 |
| 2022-10-01 | $300.00K 10-K · filed 2024-12-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kairos Pharma, LTD. (KAPA) | United States | $0.041B | |
| SCYNEXIS INC (SCYX) | United States | $0.045B | |
| PDS Biotechnology Corp (PDSB) | United States | $0.045B | |
| Incannex Healthcare Inc. (IXHL) | $0.040B | -22.32 | |
| Grace Therapeutics, Inc. (GRCE) | $0.046B | -1.83 | |
| Karyopharm Therapeutics Inc. (KPTI) | United States | $0.039B | -0.98 |
| Edesa Biotech, Inc. (EDSA) | Canada | $0.039B | |
| Werewolf Therapeutics, Inc. (HOWL) | United States | $0.047B | |
| CervoMed Inc. (CRVO) | United States | $0.038B | -1.39 |
| Celularity Inc (CELU) | United States | $0.038B | -0.34 |